SCHEMBL10180980

SCHEMBL10180980

CCC(=O)Oc1c(F)cc(F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.39
ESR1 P03372 2/20 0.39
HIF1A Q16665 2/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.38
ACHE P22303 3/20 0.38
ALOX15 P16050 1/20 0.38
POLB P06746 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
ELANE P08246 1/20 0.36
RIPK1 Q13546 1/20 0.36
ACLY P53396 1/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
ERN1 O75460 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19543201 0.86 ACHE (0.39) KMT2AESR1HIF1ARECQLSMN1; SMN2
SCHEMBL10181075 0.85 ALOX15 (0.41) KMT2AGAAALOX15CES2CES1
SCHEMBL15754940 0.83 CES2 (0.39) KMT2ASMN1; SMN2GAACES2CES1
SCHEMBL29009858 0.82 KMT2A (0.43) KMT2ARECQLSMN1; SMN2ALOX15
SCHEMBL1995471 0.82 ESR1 (0.40) KMT2AESR1HIF1ARECQLSMN1; SMN2
SCHEMBL1992937 0.80 KMT2A (0.45) KMT2AESR1HIF1ARECQLSMN1; SMN2
SCHEMBL18190917 0.80 CES2 (0.36) KMT2AGAACES2CES1CYP4F2
SCHEMBL2001585 0.79 ALOX15 (0.41) KMT2AESR1HIF1ARECQLSMN1; SMN2
SCHEMBL6622645 0.78 GPR17 (0.36) KMT2AGAAPOLBCES2CES1
SCHEMBL15438939 0.78 MAPT (0.35) KMT2AGAAPOLBCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364251-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES CIDARA THERAPEUTICS, INC. 2023-11-16 US disclosed
CN-107011326-B Fungicidal pyrazoles compound FMC公司 2019-11-12 CN disclosed
CN-107011326-A Fungicidal pyrazoles compound 纳幕尔杜邦公司 2017-08-04 CN disclosed
CN-104112870-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEM CORP 2014-10-22 CN disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 US disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 EP disclosed
CN-102484281-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEM CORP 2012-05-30 CN disclosed
CN-102421756-A fungicidal pyrazole compounds DU PONT 2012-04-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364251-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES DNPEP, NPEPPS, DHFR KMT2A 2734/4885ESR1 4015/4885HIF1A 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.